Industry news

India moving closer to implementing price controls on medical devices

Varun Saxena / FierceMedicalDevices

The Indian government is forging ahead with its plan to put price controls on medical devices, the most controversial element of an array of reforms designed to bolster the use and manufacture of devices in India.

Ripple from U.S. biotech boom drives U.K. life sci funding to 10-year high

Nick Paul Taylor / Fierce Biotech

More evidence has emerged that the ripples emanating out of the U.S. biotech boom are raising boats on the other side of the Atlantic. The latest data come from the UK Bioindustry Association (BIA) and Evaluate, which calculated that life science funding in the United Kingdom is at its highest level in at least a decade.

Russian researchers develop next gen cardiograph scanning

Marchmont Innovation News

The Russian Quantum Center (RQC) is developing ultrasensitive sensors based on monocrystal garnet ferrite film to diagnose possible infarction developments in a patient, RQC announced . 

Financially motivated hackers break into 3 major pharma companies in 18 months

Nick Paul Taylor / Fierce Biotech IT

More evidence has emerged that sophisticated hacking rings are targeting pharma companies for financial gain. The latest report accuses a hacking group of breaking into the systems of three major European pharma companies over the space of 18 months

13 July 2015

Epic Sciences Appoints Dr. Greg Critchfield to Board of Directors

Epic Sciences, Inc. ("Epic Sciences"), a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences' board of directors. As current chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc., Dr. Critchfield has more than 30 years of experience in the clinical pathology and diagnostics space.

VC investments hold steady in Q2, IPOs pick up steam

Brian Orelli / BioWorld

It wasn't the perfect second quarter, but we'll take it. You'll recall, U.S. investments in private companies tracked by BioWorld in the first quarter of the year started off like gangbusters, more than doubling the funding in the year-ago quarter. IPOs, on the other hand, left something to be desired. 

Top 5 vaccines by 2020

FierceVaccnines

Though it picked up some steam in 2014, Prevnar--anticipated to be the world's top shot in 2020--showed some signs of slowing in this year's EvaluatePharma World Preview 2015 report. According to the analysts, the shot--which last year was expected to haul in $6.08 billion in sales, will take in $5.83 billion in 2020. Still, though, enough to make it far and away the world's top vaccine in 5 years.

Retooling, not deals, is driving biopharma R&D efficiency

Marie Powers / BioWorld

Drugmakers are beginning to lower the cost and improve the efficiency of their R&D operations, and not just by slashing head count and shuttering facilities, according to a report from the Tufts Center for the Study of Drug Development (CSDD). The report, Profiles of New Approaches to Improving the Efficiency and Performance of Pharmaceutical Drug Development, concluded that biopharmas are launching successful initiatives in four principal areas.

India aims at U.S. FDA standards on drugs with name change afoot

EJ Lane / FeircePharmaAsia

Indian policymakers say one way to break the cycle of repeated manufacturing violations that freeze drugmakers out of the U.S. market is to adopt U.S. FDA rules wholesale domestically--and that may happen soon.

10 July 2015

Clearside Biomedical, Inc. to Present at International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical Meeting

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present at the 2015 International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin, Germany on Friday, July 10. Dr. Noronha’s presentation“Using suprachoroidal administration as an approach to treat noninfectious uveitis – from concept through clinical data” will be part of the afternoon Drug Delivery session.